| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5618821 | Molecular Metabolism | 2016 | 10 Pages |
Abstract
We conclude that pharmacological inhibition of FAP enhances levels of FGF21 in obese mice to provide robust metabolic benefits not observed in lean animals, thus validating this enzyme as a novel drug target for the treatment of obesity and diabetes.
Related Topics
Life Sciences
Neuroscience
Endocrine and Autonomic Systems
Authors
Miguel Angel Sánchez-Garrido, Kirk M. Habegger, Christoffer Clemmensen, Cassie Holleman, Timo D. Müller, Diego Perez-Tilve, Pengyun Li, Archita S. Agrawal, Brian Finan, Daniel J. Drucker, Matthias H. Tschöp, Richard D. DiMarchi, Alexei Kharitonenkov,